1. Home
  2. JAZZ vs CFR Comparison

JAZZ vs CFR Comparison

Compare JAZZ & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAZZ
  • CFR
  • Stock Information
  • Founded
  • JAZZ 2003
  • CFR 1868
  • Country
  • JAZZ Ireland
  • CFR United States
  • Employees
  • JAZZ N/A
  • CFR N/A
  • Industry
  • JAZZ Biotechnology: Pharmaceutical Preparations
  • CFR Major Banks
  • Sector
  • JAZZ Health Care
  • CFR Finance
  • Exchange
  • JAZZ Nasdaq
  • CFR Nasdaq
  • Market Cap
  • JAZZ 7.7B
  • CFR 8.0B
  • IPO Year
  • JAZZ 2007
  • CFR N/A
  • Fundamental
  • Price
  • JAZZ $126.54
  • CFR $127.45
  • Analyst Decision
  • JAZZ Strong Buy
  • CFR Hold
  • Analyst Count
  • JAZZ 14
  • CFR 16
  • Target Price
  • JAZZ $178.93
  • CFR $136.50
  • AVG Volume (30 Days)
  • JAZZ 691.3K
  • CFR 414.8K
  • Earning Date
  • JAZZ 11-05-2025
  • CFR 10-30-2025
  • Dividend Yield
  • JAZZ N/A
  • CFR 3.20%
  • EPS Growth
  • JAZZ N/A
  • CFR 13.33
  • EPS
  • JAZZ N/A
  • CFR 9.29
  • Revenue
  • JAZZ $4,086,695,000.00
  • CFR $2,079,741,000.00
  • Revenue This Year
  • JAZZ $5.65
  • CFR $13.32
  • Revenue Next Year
  • JAZZ $5.79
  • CFR $4.15
  • P/E Ratio
  • JAZZ N/A
  • CFR $13.46
  • Revenue Growth
  • JAZZ 4.52
  • CFR 6.87
  • 52 Week Low
  • JAZZ $95.49
  • CFR $100.31
  • 52 Week High
  • JAZZ $148.06
  • CFR $147.64
  • Technical
  • Relative Strength Index (RSI)
  • JAZZ 56.53
  • CFR 46.85
  • Support Level
  • JAZZ $123.88
  • CFR $126.62
  • Resistance Level
  • JAZZ $129.50
  • CFR $128.13
  • Average True Range (ATR)
  • JAZZ 3.03
  • CFR 2.16
  • MACD
  • JAZZ -0.63
  • CFR -0.14
  • Stochastic Oscillator
  • JAZZ 29.24
  • CFR 27.52

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

About CFR Cullen/Frost Bankers Inc.

Cullen/Frost is a regional US bank with around $50 billion in assets (as of mid-2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.

Share on Social Networks: